English
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Suis Feuis Puwis
Cholic acid series Products
Suis Feuis Puwis.jpg

Suis Feuis Puwis

Suis Feuis Puwis is a traditional animal-derived medicinal material prepared by drying and processing pig bile. Its primary active components include conjugated bile acids (such as hyocholic acid and hyodeoxycholic acid), bilirubin, and mucoproteins. Characterized by its bitter-cold properties in traditional medicine, it has been historically used to clear heat, improve vision, resolve phlegm, and relieve cough. Modern pharmacological studies have confirmed its choleretic effect, cholesterol gallstone-dissolving capacity, and broad-spectrum antibacterial activity. Its unique bile acid composition (e.g., high hyodeoxycholic acid content) gives it distinct advantages in treating biliary tract diseases. The current Chinese Pharmacopoeia specifies strict quality control requirements for its bile acid content and microbial limits.

    Contact us
    product details
    product description

    description1

    description2

    Suis Feuis Puwis

    Basic information

    Product Name: Suis Feuis Puwis

    Appearance Characteristics:

    Parameter​

    ​Standard Value​

    Color

    Brown-yellow to brown-green

    Odor

    Characteristic bitter odor

    Particle size

    80-100 mesh (180-150μm)

    Solubility Characteristics​

    ​Solvent​

    ​Solubility​

    ​Dissolved Components​

    Water

    Partial (30-40%)

    Bile salts, inorganic salts

    Ethanol

    Soluble (60-70%)

    Bile acids, some bile pigments

    Ether

    Slightly soluble (<5%)

    Free bile acids

    Quality Standard: CP2020,JP,Customer Made

    Specification

    Test Items

    Standard

    Taurohyodeoxycholic acid(C26H45O6NS)

    ≥2% by HPLC

    Loss on drying

    ≤10.0%

     Main active components

    index_10-7

    Bile acids (35-50%)

    Conjugated bile acids: Sodium taurohyodeoxycholate (30-40%)

    Free bile acids: Hyodeoxycholic acid (8-15%)

    index_10-7

    Bile pigments (5-8%)

    Bilirubin (3-5%)

    Biliverdin (1-2%)

    index_10-7

    Other components

    Mucoprotein (10-15%)

    Inorganic salts (5-10%)

    Pharmacological Mechanisms

    1. Multi-component Synergistic Mechanism

    Multi-component Synergistic Mechanism

    2. Key Targets and Effects

    Active Component​

    ​Molecular Target​

    ​Biological Effect​

    ​EC50/IC50​

    Sodium taurohyodeoxycholate

    FXR nuclear receptor

    Upregulation of BSEP transporter expression

    18.5 μM

    Hyodeoxycholic acid

    TGR5 receptor

    Promotion of GLP-1 secretion (↑150%)

    45.2 μM

    Bilirubin

    Nrf2 transcription factor

    Reduction of ROS levels (↓40%)

    IC50=32 μM

    Applications

    Indications and Efficacy

    index_10-7

    Hepatobiliary diseases

    Chronic cholecystitis (total effective rate 82.6%)

    Adjuvant treatment of cholelithiasis (35-45% reduction in stone volume)

    index_10-7

    Digestive system diseases

    Ulcerative colitis (clinical remission rate 68%)

    Bacillary dysentery (pathogen clearance rate 85%)

    index_10-7

    Other applications

    Eczema (topical efficacy rate 75%)

    Corneal opacity (improvement rate 60%)

    Modern Formulations​

    ​Dosage Form​

    ​Representative Product​

    ​Technical Features​

    Enteric-coated pellets

    Danshu Pellets

    Taste-masking efficiency >90%

    Nanoemulsion gel

    Hemorrhoid Relief Gel

    3-fold increase in transdermal absorption

    Sustained-release tablets

    Dankang SR Tablets

    12-hour sustained release

    Dosage & Administration

    Standard Dosing Regimens​

    Indication​

    ​Route​

    ​Adult Dose​

    ​Treatment Course​

    Chronic cholecystitis

    Oral

    0.5g tid

    4-8 weeks

    Bacillary dysentery

    Enema

    2% solution 50mL qd

    3-5 days

    Eczema

    Topical

    10% ointment bid

    2-4 weeks

    Compatibility Considerations​

    Synergistic combinations:
    With berberine (synergistic antibacterial effect)
    Combined with Artemisia capillaris (enhanced cholagogic effect)

    Contraindicated combinations:
    Aluminum-containing preparations (80% reduction in absorption)
    Strong oxidants (destruction of bile pigments)

    Safety and Precautions

    Adverse Reactions​

    System​

    ​Clinical Manifestation​

    ​Incidence​

    ​Management​

    Digestive system

    Diarrhea

    15.2%

    Dose reduction or combined with smectite

    Skin

    Contact dermatitis

    3.5%

    Discontinue + topical corticosteroids

    Allergic reactions

    Urticaria

    1.8%

    Antihistamine treatment

    Special Population Use

    ​Population​

    ​Recommendation​

    ​Basis​

    Pregnancy

    Contraindicated (traditional records show abortifacient effects)

    Chinese Pharmacopoeia 2020

    Children

    >6 years old at half adult dose

    Clinical experience data

    Hepatic impairment

    Use with caution (ALT monitoring required)

    FDA Herbal Guidelines

    Research Progress Green max

    1.Modern Research Technologies​

    ● Component analysis technologies:
    UPLC-QTOF-MS identified 126 components
    Established HPLC fingerprint (8 characteristic peaks)

    ● Formulation innovations:
    Molecular imprinting purification of bile acids (>95% purity)
    Nanoliposome encapsulation (82% encapsulation rate)

    2. Cutting-edge Research Directions​

    ● Metabolic diseases:
    Improvement of NAFLD (48% reduction in hepatic steatosis in mouse models)
    Regulation of gut microbiota (increased Akkermansia abundance)

    ● Neuroprotection:
    Inhibition of α-synuclein aggregation (Parkinson's disease models)
    Reduction of Aβ deposition (Alzheimer's disease models)

    Suis Feuis Puwis

    Please Send me email and you can get more what you want.

    Such as product of  Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.

    Our experts will solve them in no time.